Soleno Therapeutics, Inc.

Based on the provided multi-faceted analysis, here is a comprehensive assessment of SLNO.

Technical Analysis The technical picture for SLNO is deeply concerning. The stock is in a pronounced and accelerating downtrend, having lost nearly 58% of its value over the past year and trading just above its 52-week low. Its extreme negative beta indicates it moves sharply against the market, adding a layer of unpredictability. While the stock appears oversold and may be testing a support level, the overwhelming momentum is negative.

Fundamental Analysis Fundamentally, SLNO presents a mixed but intriguing profile. Its recent Q3 performance was exceptionally strong, with revenue doubling and a swing to a 39.4% net margin, showcasing high profit potential. The company's balance sheet is a major strength, being virtually debt-free with ample cash reserves. However, operational efficiency is a concern, particularly the extremely high days of inventory outstanding, which suggests potential challenges in managing its assets.

Valuation & Risk Valuation is challenging; while the forward P/E suggests the market is pricing in growth, the lack of peer data makes it difficult to assess if this is reasonable. The risk profile is exceptionally high, characterized by extreme volatility, a severe negative beta, and potential liquidity issues due to low market participation.

**Buy Recommendation**

Based on the comprehensive analysis, SLNO is not recommended for purchase at this time. While the company possesses a remarkably strong balance sheet and demonstrated high profitability in its latest quarter, these positives are overwhelmingly offset by severe technical weakness and an exceptionally high risk profile. The extreme volatility, persistent downtrend, and lack of a clear valuation anchor present significant risks that outweigh the potential fundamental upside for most investors. A cautious approach is warranted, with a recommendation to monitor for a sustained reversal in price momentum and improved operational efficiency before considering an investment.

RockFlow Model Forecast: Three Scenarios for 2026

Based on the provided analysis, the 12-month outlook for SLNO is highly speculative and weighted toward continued volatility.

Key catalysts for a potential recovery hinge on the company demonstrating that its impressive Q3 profitability is sustainable and not an anomaly, coupled with tangible improvements in operational efficiency, particularly in reducing its bloated inventory levels. The primary risks are exceptionally high, dominated by the severe technical downtrend, extreme price volatility, and the stock's negative beta, which could lead to further sharp declines unrelated to company-specific news. Given the extreme risk profile and lack of analyst targets, a specific price range is imprudent to project; the stock is more likely to experience wide swings, with a bullish case requiring a break above key technical resistance levels, while the bearish case could see a test of new lows if negative momentum persists.

Wall Street Consensus

Most Wall Street analysts are optimistic about Soleno Therapeutics, Inc.'s 12-month outlook, with consensus target around $37.24, indicating expected upside potential.

Overall, SLNO has investment potential but also faces challenges. Here are key factors to weigh before investing.

SLNO has demonstrated significant weakness with substantial declines across multiple timeframes. The stock has experienced a dramatic drawdown of nearly 58% over the past year, reflecting severe downside pressure and investor pessimism.

The short-term performance shows accelerating losses, declining 12.29% over one month and 19.59% over three months. SLNO has significantly underperformed the market by approximately 20% during this period, exacerbated by its extreme negative beta indicating counter-market volatility.

Currently trading just 0.95% above its 52-week low of $36.89, SLNO appears deeply oversold within its wide annual range of $36.89-$90.32. The minimal distance from recent lows suggests potential support testing, though the persistent downtrend indicates continued selling pressure.

Revenue & Profitability SLNO demonstrated a significant rebound in Q3 2025, with revenue doubling to $66 million from $32.7 million in Q2 and swinging to a strong net income of $26 million (39.4% net margin). This follows a net loss in the prior quarter, highlighting substantial improvement in profitability driven by robust revenue growth and an exceptional gross profit margin of over 98%. The volatility between quarters indicates a potentially lumpy revenue model but shows strong underlying earning power when operational.

Financial Health The company exhibits exceptionally strong liquidity, with a current ratio of 16.1 and a cash ratio of 7.4, indicating ample cash reserves relative to obligations. With a minimal debt ratio of 0.47% and a strong interest coverage ratio of 15.9, SLNO is virtually debt-free and possesses a very low-risk balance sheet. Operating cash flow generation is solid, further reinforcing its financial stability.

Operational Efficiency Operational efficiency shows mixed signals, with a respectable ROE of 5.3% in Q3 but a relatively low asset turnover of 0.11, suggesting the company is not fully leveraging its asset base for revenue generation. The negative cash conversion cycle of -81 days is a strength, indicating the company collects from customers before paying suppliers. However, the extremely high days of inventory outstanding (526 days) points to potential inefficiencies in inventory management.

Valuation Level SLNO's valuation presents contradictory signals across different metrics due to its negative TTM earnings. The negative trailing PE ratio is not meaningful, while the forward PE of approximately 34.6 suggests a premium valuation based on anticipated future profitability. Other metrics like the high EV/EBITDA of 120.4 and a negative PEG ratio further complicate the picture, indicating the market is pricing in significant growth expectations that are not yet reflected in current earnings.

Peer Comparison A direct peer comparison is not possible as industry average data is unavailable. The absence of this contextual benchmark makes it challenging to determine if SLNO's forward PE of 34.6 and PB ratio of 4.04 represent a sector premium or discount. Valuation analysis would be significantly enhanced with industry-specific multiples to properly contextualize these metrics against comparable companies.

Volatility Risk: SLNO exhibits extreme volatility risk, as evidenced by its remarkably negative Beta of -3.182, which implies the stock tends to move sharply in the opposite direction of the broader market. This characteristic is further confirmed by a severe 1-year maximum drawdown of -57.92%, indicating a history of profound price depreciation and substantial investor losses. These metrics collectively signal very high and erratic price fluctuations.

Other Risks: The absence of reported short interest does not inherently indicate a lower risk profile, as it often reflects extremely low liquidity or limited market participation, which can amplify price impacts from trades. This lack of trading activity presents a significant liquidity risk, potentially making it difficult to execute trades without causing substantial price swings. Investors should be cautious of these structural market risks alongside the stock's inherent volatility.